Cardiorenal intersection: Crossroads to the future;Interseção cardiorrenal: Confluência para o futuro

Arquivos Brasileiros de Cardiologia

Volumn 88, Issue 1, 2007, Pages 100-108

  McCullough, Peter A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Aortic sclerosis; Atherosclerosis; Cardiac arrhythmias; Cardiovascular disease; Chronic kidney disease; Diabetes; Heart failure; Hypertension; Left ventricular hypertrophy; Microalbuminuria; Mitral annular calcification; Nephropathy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALISKIREN; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ASCORBIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; CYANOCOBALAMIN; DETEMIR INSULIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; EZETIMIBE PLUS SIMVASTATIN; FIBRINOGEN RECEPTOR ANTAGONIST; FOLIC ACID; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN GLARGINE; METFORMIN; NICERITROL; PLACEBO; PYRAZOLE DERIVATIVE; ROSUVASTATIN; SEVELAMER; SIMVASTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROGENESIS; CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HOMOCYSTINURIA; HUMAN; HYPERTENSION; INFLAMMATION; LIFESTYLE MODIFICATION; META ANALYSIS; MONOTHERAPY; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT REDUCTION;

EID: 33947324699     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2007000100020     Document Type: Review

References (58)

1. McCullough PA. Cardiorenal risk: an important clinical intersection. Rev Cardiovasc Med 2002;3:71-6.
2. Luke RG. Chronic renal failure - a vasculopathic state. N Engl J Med 1998;339:841-3.
3. Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 2001;38:S26-S29.
4. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9:S16-S23.
5. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32:S112-S119.
6. Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A. Cystatin C as a marker of GFR - history, indications, and future research. Clin Biochem. 2005; 38(1):1-8.
7. McCullough PA, Brown WW, McGill JB, Collins AJ, Chen SC, Li S, Singh AK, Narva AS, Herman WH, Bakris GL, Jurkovitz CT, Norris KC, Pergola P, Klag MJ, for the KEEP Investigators. Independent components of chronic kidney disease as a cardiovascular risk factor; results from the Kidney Early Evaluation Program (KEEP). J Am Coll Cardiol 2005;45(3)424A.
8. Zalesin KC, McCullough PA. Bariatric surgery for morbid obesity: risks and benefits in chronic kidney disease patients. Adv Chronic Kidney Dis. 2006; 13(4):403-17
9. Nori Janosz K, Koenig K, Leff C, Miller W, McCullough P. How much weight needs to be lost to resolve type 2 diabetes? Obesity Research 2005;13, A59 (229-P
10. Painter PL, Hector L, Ray K, et al. Effects of exercise training on coronary heart disease risk factors in renal transplant recipients. Am J Kidney Dis 2003;42:362-9.
11. Prichard S. Risk factors for coronary artery disease in patients with renal failure. Am J Med Sci 2003;325:209-13.
12. Wierzbicki AS. Rimonabant: endocannabinoid inhibition for the metabolic syndrome. Int J Clin Pract. 2006; 60(12):1697-1706.
13. Lamounier-Zepter V, Bornstein SR, Ehrhart-Bornstein M. Mechanisms of obesity-related hypertension. Horm Metab Res. 2004; 36(6):376-80.
14. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006; 368(9545):1449-56.
15. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2):227-39. Review. Erratum in: Circulation. 2004; 110(6):763.
16. Nori Janosz KE, Miller WM, Odom J, Lillystone M, McCullough PA. Optimal diabetes management during medical weight loss for cardiovascular risk reduction. Expert Rev Cardiovasc Ther. 2005; 3(4):761-75.
17. Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol. 2003;2(1):33-47.
18. Avram MM, Fein PA, Antignani A, et al. Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis. Am J Med 1989;87:55N-60N
19. Yerkey MW, Kernis SJ, Franklin BA, Sandberg KR, McCullough PA. Renal dysfunction and acceleration of coronary disease. Heart. 2004; 90(8):961-6.
20. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001; 59(1):260-9.
21. Vidt DG, Harris S, McTaggart F, Ditmarsch M, Sager PT, Sorof JM. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol. 2006; 97(11):1602-6. Epub 2006 Apr 7.
22. Schaefer EJ, Asztalos BF. Cholesteryl ester transfer protein inhibition, highdensity lipoprotein metabolism and heart disease risk reduction. Curr Opin Lipidol. 2006;17(4):394-8.
23. Bachmann J, Tepel M, Raidt H, et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995;6:121-5
24. Abdel-Raheem MM, Hebert B, Potti A, et al. Hyperhomocysteinemia and the risk of thromboembolic phenomenon in patients with chronic renal failure. Thromb Res 2002;105:299-302.
25. Bostom AG, Shemin D, Lapane KL, et al. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996;49:147-52.
26. Bleys J, Miller ER 3rd, Pastor-Barriuso R, Appel LJ, Guallar E. Vitamin-mineral supplementation and the progression of atherosclerosis: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2006; 84(4):880-7; quiz 954-5.
27. Gonin JM. Folic acid supplementation to prevent adverse events in individuals with chronic kidney disease and end stage renal disease. Curr Opin Nephrol Hypertens. 2005; 14(3):277-81.
28. Kronenberg F, Neyer U, Lhotta K, et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 1999;10:1027-36.
29. Docci D, Manzoni G, Bilancioni R, et al. Serum lipoprotein(a) and coronary artery disease in uremic patients on chronic hemodialysis. Int J Artif Organs 1994;17:41-5.
30. Nakahama H, Nakanishi T, Uyama O, et al. Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis. Ren Fail 1993;15:189-93.
31. van Herk T, Brussee J, van den Nieuwendijk AM, van der Klein PA, IJzerman AP, Stannek C, Burmeister A, Lorenzen A. Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003; 46(18):3945-51.
32. Roberts MA, Hare DL, Ratnaike S, Ierino FL. Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis. 2006; 48(3):341-60.
33. Tepel M, van der GM, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003;107:992-5.
34. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli AL. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006; 354(26):2773-82.
35. Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, Voudris V, Pavlides G, Buller CE, Kremastinos D, Cokkinos DV. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004 Nov 2;110(18):2837-42. Epub 2004 Oct 18. Erratum in: Circulation. 2005 Jan 25;111(3):379.
36. Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997;8:475-86.
37. Scalera F, Kielstein JT, Martens-Lobenhoffer J, Postel SC, Tager M, Bode-Boger SM. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol. 2005;16(4):892-8. Epub 2005 Feb 23.
38. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355(20):2085-98.
39. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355(20):2071-84.
40. Stefoni S, Cianciolo G, Donati G, et al. Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int 2002;61:324-35.
41. Kanaan RA, Kanaan LA. Transforming growth factor beta1, bone connection. Med Sci Monit. 2006; 12(8):RA164-9. Epub 2006 Jul 12.
42. Andreotti F, Porto I, Crea F, Maseri A. Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies. Heart. 2002 Feb;87(2):107-12.
43. Tracy RP. Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Pract Suppl. 2003; (134):10-7.
44. Panichi V, De Pietro S, Andreini B, et al. Cytokine production in haemodiafiltration: a multicentre study. Nephrol Dial Transplant 1998;13:1737-44.
45. Westhuyzen J, Healy H. Review: Biology and relevance of C-reactive protein in cardiovascular and renal disease. Ann Clin Lab Sci 2000;30:133-43.
46. McCullough PA. Cardiovascular disease in chronic kidney disease from a cardiologist's perspective. Curr Opin Nephrol Hypertens. 2004; 13(6):591-600. NLM CIT. ID: 15483448
47. Miller WM, Nori Janosz KE, Yanez J, McCullough PA. Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease. Expert Rev Cardiovasc Ther. 2005 Jul;3(4):743-59.
48. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83.
49. McCullough PA. Effect of lipid modification on progression of coronary calcification. J Am Soc Nephrol. 2005; 16 Suppl 2:S115-9.
50. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
51. Achenbach S, Ropers D, Pohle K, Leber A, Thilo C, Knez A, Menendez T, Maeffert R, Kusus M, Regenfus M, Bickel A, Haberl R, Steinbeck G, Moshage W, Daniel WG. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation 2002; 106: 1077-82
52. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med. 1998; 339(27):1972-8.
53. Suki W, Zabaneh R, Cangiano J, et al. The DCOR trial - a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients. Amer Soc Nephrol Renal Week 2005; November 8-13, 2005; Philadelphia, Pennsylvania. Abstract PO745.
54. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005 Jul 21;353(3):238-48. Erratum in: N Engl J Med. 2005;353(15):1640.
55. Escolar G, Diaz-Ricart M, Cases A. Uremic platelet dysfunction: past and present. Curr Hematol Rep. 2005; 4(5):359-67.
56. Chew DP, Bhatt DL, Kimball W, Henry TD, Berger P, McCullough PA, Feit F, Bittl JA, Lincoff AM. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol. 2003; 92(8):919-23.
57. McCullough PA. Why is chronic kidney disease the "spoiler" for cardiovascular outcomes? J Am Coll Cardiol. 2003 Mar 5;41(5):725-8.
58. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13):1296-305.